De Rosa G, Gobbo M L, De Renzo A, Notaro R, Garofalo S, Grimaldi M, Apuzzo A, Chiurazzi F, Picardi M, Matarazzo M, Rotoli B
Division of Hematology, Federico II University Medical School, Naples, Italy.
Am J Hematol. 1997 Jun;55(2):77-82. doi: 10.1002/(sici)1096-8652(199706)55:2<77::aid-ajh5>3.0.co;2-#.
Starting from the observation that a number of consecutive patients with non-Hodgkin's lymphoma (NHL) resulted positive for hepatitis C virus (HCV) antibodies on routine testing, we set up a survey for HCV contact prevalence in all patients with lymphoproliferative disorders (LPD) followed in our institution. We searched for HCV antibodies by a third-generation ELISA technique, followed by a confirmation test (RIBA III); serum viral RNA and HCV genotype were investigated by a RT-PCR technique. We screened a total of 315 patients suffering from B-NHL (91), multiple myeloma (56), MGUS (48), chronic lymphocytic leukemia (57), Waldentrom's macroglobulinemia (13), Hodgkin's disease (HD)(43), and T-NHL (9). While only 1 of 52 patients with a non-B-LPD (HD or T-NHL) had signs of HCV contact (i.e., 1.9%, which is in the range of the normal population in the South of Italy), 59 of 263 patients with a B-LPD (22.4%) had HCV antibodies or RNA, or both, with no major differences among the various types of disorders, except for WM, in which the rate was higher (61.5%). The same prevalence was found for patients tested at diagnosis or during the follow-up, and in transfused or never-transfused patients. Only a few patients were aware of having a liver disease; one-half of HCV-positive patients never had transaminase increase. A review of data from Central and Northern Italy is included, showing similar findings; a report from Japan has confirmed such an association, while limited surveys in England have not revealed any correlation. These findings may have important biological and clinical implications.
从一系列非霍奇金淋巴瘤（NHL）患者在常规检测中丙型肝炎病毒（HCV）抗体呈阳性这一观察结果出发，我们对在本机构接受治疗的所有淋巴增生性疾病（LPD）患者进行了HCV感染率调查。我们采用第三代酶联免疫吸附测定（ELISA）技术检测HCV抗体，随后进行确认试验（重组免疫印迹分析III型，RIBA III）；采用逆转录聚合酶链反应（RT-PCR）技术检测血清病毒RNA和HCV基因型。我们共筛查了315例患有B细胞非霍奇金淋巴瘤（91例）、多发性骨髓瘤（56例）、意义未明的单克隆丙种球蛋白血症（MGUS，48例）、慢性淋巴细胞白血病（57例）、华氏巨球蛋白血症（13例）、霍奇金病（HD，43例）和T细胞非霍奇金淋巴瘤（9例）的患者。在52例非B细胞LPD（HD或T细胞非霍奇金淋巴瘤）患者中，只有1例有HCV感染迹象（即1.9%，处于意大利南部正常人群范围内），而在263例B细胞LPD患者中，59例（22.4%）有HCV抗体或RNA，或两者皆有，除华氏巨球蛋白血症（其感染率较高，为61.5%）外，各类疾病之间无显著差异。在诊断时或随访期间接受检测的患者以及输血或未输血患者中，发现了相同的感染率。只有少数患者知道自己患有肝病；HCV阳性患者中有一半的转氨酶从未升高。本文还纳入了意大利中部和北部的数据回顾，结果显示类似的发现；日本的一份报告证实了这种关联，而英国的有限调查未发现任何相关性。这些发现可能具有重要的生物学和临床意义。
